Re: Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer

European Urology

Volumn 59, Issue 6, 2011, Pages 1066-1067

  Kliment, Jan ^a  

^a Physics and Informatics   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG EXPOSURE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; SALVAGE THERAPY; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 79955578125     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.03.042     Document Type: Note

References (4)

1. Smith MR, Cook R, Lee KA, Nelson JB. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. In press. DOI:10.1002/cncr.25762.
2. J. Hofland, W.M. van Weerden, and N.F.J. Dits Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer Cancer Res 70 2010 1256 1264
3. H.I. Scher, T.M. Beer, and S.C. Hugano Antitumor activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437 1446
4. A.H. Reid, G. Attard, and D.C. Danila Significant and sustained antitumor activity in postdocetaxel,castrationresistant prostate cancer with the CYP17 inhibitor abiraterone acetate J Clin Oncol 28 2010 1489 1495